Comparison of wavefront-optimized and wavefront-guided LASIK using a high-resolution aberrometer

Session Details

Session Title: LASIK Outcomes and Refinements

Session Date/Time: Monday 09/10/2017 | 14:30-15:50

Paper Time: 15:07

Venue: Room 4.4

First Author: : E.Manche USA

Co Author(s): :    W. Lee                    

Abstract Details

Purpose:

To prospectively compare outcomes between wavefront-guided LASIK and wavefront-optimized LASIK in the treatment of myopia and compound myopic astigmatism.  Outcome measures include high contrast snellen acuity, low contrast snellen acuity (5 and 25%), safety, predictability, efficacy and higher order aberration analysis.

Setting:

Stanford University School of Medicine

Methods:

One hundred and eighty eyes of 90 consecutive patients were treated with wavefront-guided and wavefront-optimized LASIK.  Wavefront measurements were perfomed using the high-resolution iDesign aberrometer.  One eye was treated with wavefront-guided LASIK using the AMO Visx S4 IR excimer laser and the fellow eye was treated with wavefront-optimized LASIK using the Allegretto Wave Eye-Q excimer laser.  Eyes were randomized according to ocular dominance.  Mean pre-operative spherical equivalent refraction was -4.67 +/- 2.31 and -4.95 +/-2.26 in the wavefront-guided group and wavefront-optimized group respectively. The mean cylinder was +0.69 +/-0.68 and +0.65 +/-0.60 in the wavefront-guided group and wavefront-optimized group respectively.

Results:

At the six-month post-op visit the mean spherical equivalent refraction was +0.27 +/- 0.15 in the wavefront-guided group and -0.23 +/- 0.39 in the wavefront-optimized group respectively.  At the six-month post-op visit, mean cylinder was reduced to +0.23 +/- 0.21 in the wavefront-guided group and +0.27 +/- 0.33 in the wavefront-optimized group. There were no statistically significant differences in low contrast visual acuity and higher order aberrations between the two groups.

Conclusions:

Wavefront-guided and wavefront-optimized LASIK have similar clinical outcomes with excellent safety, efficacy and predictability in both groups.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented